Mylotarg

Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS

Vyxeos for Induction of Low- or Intermediate-risk.

Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia

Prospective Study of Mylotarg and G-CSF in Acute Myeloid Leukemia Treatment

Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)

DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AML

Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS

Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS

Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia

Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care